| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |